Literature DB >> 17350571

Wild-type p53: tumors can't stand it.

Michael B Kastan1.   

Abstract

Most malignant tumors disrupt the p53 signaling pathway in order to grow and survive. Although many genes in addition to p53 are mutated in tumors, recent studies by Ventura et al. (2007) and Xue et al. (2007) suggest that restoring p53 function alone is sufficient to cause regression of several different tumor types in mice and thus might represent a potent therapeutic strategy to treat certain human cancers. Martins et al. (2006) also demonstrate that restoration of p53 activity results in tumor regression but add the sobering caveat that tumors may be able to quickly generate resistance by finding other ways to disrupt the p53 pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350571     DOI: 10.1016/j.cell.2007.02.022

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  60 in total

1.  5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage.

Authors:  Jing Chen; Michael B Kastan
Journal:  Genes Dev       Date:  2010-09-13       Impact factor: 11.361

2.  miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42.

Authors:  Seong-Yeon Park; Jung Hyun Lee; Minju Ha; Jin-Wu Nam; V Narry Kim
Journal:  Nat Struct Mol Biol       Date:  2008-12-14       Impact factor: 15.369

3.  A systems biology approach to personalizing therapeutic combinations.

Authors:  Lawrence N Kwong; Timothy P Heffernan; Lynda Chin
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397

4.  Induction of SOX4 by DNA damage is critical for p53 stabilization and function.

Authors:  Xin Pan; Jie Zhao; Wei-Na Zhang; Hui-Yan Li; Rui Mu; Tao Zhou; Hai-Ying Zhang; Wei-Li Gong; Ming Yu; Jiang-Hong Man; Pei-Jing Zhang; Ai-Ling Li; Xue-Min Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

5.  Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.

Authors:  Nektarios Barabutis; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

6.  Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.

Authors:  E M Michalak; E S Jansen; L Happo; M S Cragg; L Tai; G K Smyth; A Strasser; J M Adams; C L Scott
Journal:  Cell Death Differ       Date:  2009-01-16       Impact factor: 15.828

7.  Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Authors:  Sanjeev Shangary; Ke Ding; Su Qiu; Zaneta Nikolovska-Coleska; Joshua A Bauer; Meilan Liu; Guoping Wang; Yipin Lu; Donna McEachern; Denzil Bernard; Carol R Bradford; Thomas E Carey; Shaomeng Wang
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

8.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

9.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

10.  Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.

Authors:  Karita Peltonen; Laureen Colis; Hester Liu; Sari Jäämaa; Henna M Moore; Juulia Enbäck; Pirjo Laakkonen; Anne Vaahtokari; Richard J Jones; Taija M af Hällström; Marikki Laiho
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.